RARE
Ultragenyx
NASDAQ: RARE · HEALTHCARE · BIOTECHNOLOGY
$24.18
-1.43% today
Updated 2026-04-29
Market cap
$2.38B
P/E ratio
—
P/S ratio
3.53x
EPS (TTM)
$-5.83
Dividend yield
—
52W range
$18 – $42
Volume
2.0M
Ultragenyx (RARE) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $12.13M | $88.32M | $59.65M | $197.97M | $559.57M | $540.63M | $490.75M | $719.56M | $1.14B | $1.76B | $1.52B | $1.55B | $1.49B | $1.50B |
| Cash & equivalents | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Current assets | $10.95M | $86.44M | $55.23M | $187.49M | $450.21M | $498.11M | $244.47M | $522.37M | $851.02M | $1.30B | $856.60M | $883.90M | $732.18M | $817.12M |
| Total liabilities | $1.49M | $3.98M | $9.54M | $13.02M | $28.48M | $66.65M | $107.30M | $110.65M | $481.73M | $605.18M | $599.84M | $1.19B | $1.22B | $1.24B |
| Current liabilities | $999000.00 | $3.19M | $5.92M | $12.52M | $27.92M | $60.26M | $71.01M | $74.72M | $103.30M | $189.61M | $181.37M | $261.21M | $280.44M | $344.15M |
| Long-term debt | $216000.00 | $518000.00 | $3.42M | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — | — |
| Shareholder equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Retained earnings | $-8.15M | $-27.06M | $-74.84M | $-139.04M | $-284.66M | $-530.53M | $-832.67M | $-1.03B | $-1.43B | $-1.62B | $-2.07B | $-2.78B | $-3.39B | $-3.96B |
| Accounts receivable | $103000.00 | — | — | — | — | — | $5.17M | $12.74M | $32.84M | $23.09M | $28.43M | $40.45M | $73.39M | $121.80M |
| Inventory | — | — | — | $0.00 | $0.00 | $0.00 | $757000.00 | $7.07M | $11.55M | $13.05M | $16.23M | $26.77M | $33.97M | $45.01M |
| Goodwill | — | — | — | $0.00 | $0.00 | $0.00 | $44.41M | $44.41M | $44.41M | $44.41M | $44.41M | $44.41M | $44.41M | $44.41M |